EXCITE: Erbitux, Xeloda, Campto, Irradiation Then Excision for locally advanced rectal cancer. (North West Clinical Oncology Group-04 on behalf of the NCRI rectal cancer subgroup)
- Registry ID
- EUCTR2007-006701-25
- Source registry
- EUCTR
- Status
- Completed
- Phase
- PHASE2
- Sponsor
- University College London
- Start date
- 2008-02-11
- Completion date
- 2016-12-31
- Last update
- 2026-08-16
Conditions
- Locally advanced rectal cancer
Summary
In a phase II setting in MRI-defined locally advanced rectal cancer to assess the downstaging effectiveness of preoperative chemoradiotherapy using capecitabine/ irinotecan/cetuximab plus radiotherapy using the primary endpoint of clear (R0) circumferential resection margin rate.
Locations
View on source registry